NYSE:ADCT ADC Therapeutics (ADCT) Stock Forecast, Price & News $0.81 +0.09 (+12.53%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$0.68▼$0.8150-Day Range$0.72▼$1.6852-Week Range$0.68▼$5.75Volume345,515 shsAverage Volume518,466 shsMarket Capitalization$62.10 millionP/E RatioN/ADividend YieldN/APrice Target$8.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ADC Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside914.2% Upside$8.20 Price TargetShort InterestBearish8.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.41) to ($2.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector442nd out of 963 stocksPharmaceutical Preparations Industry188th out of 444 stocks 3.2 Analyst's Opinion Consensus RatingADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.20, ADC Therapeutics has a forecasted upside of 914.2% from its current price of $0.81.Amount of Analyst CoverageADC Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.12% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in ADC Therapeutics has recently decreased by 3.95%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADCT. Previous Next 3.0 News and Social Media Coverage News SentimentADC Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for ADC Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows3 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of ADC Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.29% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($2.41) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADC Therapeutics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ADC Therapeutics (NYSE:ADCT) StockADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Read More ADCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADCT Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for ADC Therapeutics SA Increased by Analyst (NYSE:ADCT)September 22, 2023 | americanbankingnews.comAnalysts Set Expectations for ADC Therapeutics SA's FY2024 Earnings (NYSE:ADCT)September 26, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 20, 2023 | americanbankingnews.comADC Therapeutics (NYSE:ADCT) Receives "Buy" Rating from HC WainwrightSeptember 18, 2023 | americanbankingnews.comQ3 2023 Earnings Estimate for ADC Therapeutics SA Issued By Capital One Financial (NYSE:ADCT)September 5, 2023 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics to Participate in September Investor ConferencesSeptember 5, 2023 | finance.yahoo.comADC Therapeutics to Participate in September Investor ConferencesAugust 30, 2023 | finance.yahoo.comADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)September 26, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 14, 2023 | finance.yahoo.comAtreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%August 11, 2023 | finance.yahoo.comCatalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook RaisedAugust 10, 2023 | msn.comRBC Capital Maintains Adc Therapeutics (ADCT) Outperform RecommendationAugust 10, 2023 | msn.comJP Morgan Upgrades Adc Therapeutics (ADCT)August 9, 2023 | finance.yahoo.comQ2 2023 ADC Therapeutics SA Earnings CallAugust 8, 2023 | finance.yahoo.comZoetis' (ZTS) Q2 Earnings and Revenues Surpass EstimatesAugust 8, 2023 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 8, 2023 | finance.yahoo.comADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 7, 2023 | benzinga.comA Preview Of ADC Therapeutics's EarningsAugust 7, 2023 | finance.yahoo.comMannKind (MNKD) Reports Break-Even Earnings for Q2August 4, 2023 | finance.yahoo.comUltragenyx (RARE) Q2 Loss Wider Than Expected, Revenues BeatAugust 4, 2023 | finance.yahoo.comIntra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View RaisedAugust 3, 2023 | finance.yahoo.comEditas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in FocusAugust 3, 2023 | finance.yahoo.comCorcept (CORT) Beats on Q2 Earnings, Ups '23 Sales ViewAugust 1, 2023 | finance.yahoo.comAre Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 27%?July 25, 2023 | msn.comHC Wainwright & Co. Reiterates Adc Therapeutics (ADCT) Buy RecommendationJuly 25, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Alnylam Pharma (ALNY)July 24, 2023 | finance.yahoo.comAlnylam (ALNY) to Co-Develop Hypertension Drug With RocheSee More Headlines Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADCT Company Calendar Last Earnings8/08/2023Today9/25/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ADCT CUSIPN/A CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees317Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.20 High Stock Price Forecast$12.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+914.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-155,800,000.00 Net Margins-98.33% Pretax Margin-100.29% Return on Equity-325.79% Return on Assets-35.62% Debt Debt-to-Equity Ratio2.57 Current Ratio5.12 Quick Ratio4.88 Sales & Book Value Annual Sales$184.39 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book0.70Miscellaneous Outstanding Shares76,810,000Free Float49,619,000Market Cap$62.10 million OptionableNot Optionable Beta1.01 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Ameet Mallik M.B.A. (Age 50)M.S., CEO & Director Comp: $830.03kMr. Jose I. Carmona M.B.A. (Age 51)Chief Financial Officer Dr. Patrick van Berkel Ph.D. (Age 55)Chief Scientific Officer Dr. Michael Mulkerrin Ph.D. (Age 68)Chief Technical Operations Officer Amanda HamiltonInvestor Relations OfficerMs. Susan Romanus (Age 58)Chief Compliance & Quality Officer Mr. Peter J. Graham Esq. (Age 56)Chief Legal Officer Ms. Kimberly Pope (Age 56)Sr. VP & Chief People Officer Mr. David M. Gilman (Age 50)Chief Bus. & Strategy Officer Ms. Kristen Harrington-Smith (Age 50)Chief Commercial Officer More ExecutivesKey CompetitorsAdageneNASDAQ:ADAGImmunicNASDAQ:IMUXEyenoviaNASDAQ:EYENCleneNASDAQ:CLNNSpero TherapeuticsNASDAQ:SPROView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Sold 1,216,116 shares on 8/15/2023Ownership: 1.481%XTX Topco LtdSold 59,892 shares on 8/15/2023Ownership: 0.269%Citadel Advisors LLCSold 700 shares on 8/15/2023Ownership: 0.000%Prosight Management LPBought 2,326,540 shares on 8/14/2023Ownership: 7.270%Marshall Wace LLPBought 207,379 shares on 8/14/2023Ownership: 0.475%View All Institutional Transactions ADCT Stock - Frequently Asked Questions Should I buy or sell ADC Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares. View ADCT analyst ratings or view top-rated stocks. What is ADC Therapeutics' stock price forecast for 2023? 6 brokerages have issued 1-year price objectives for ADC Therapeutics' stock. Their ADCT share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's share price to reach $8.20 in the next year. This suggests a possible upside of 914.2% from the stock's current price. View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts. How have ADCT shares performed in 2023? ADC Therapeutics' stock was trading at $3.84 at the beginning of 2023. Since then, ADCT stock has decreased by 78.9% and is now trading at $0.8085. View the best growth stocks for 2023 here. Are investors shorting ADC Therapeutics? ADC Therapeutics saw a decline in short interest in August. As of August 15th, there was short interest totaling 5,320,000 shares, a decline of 13.6% from the July 31st total of 6,160,000 shares. Based on an average daily volume of 461,400 shares, the days-to-cover ratio is presently 11.5 days. Currently, 8.5% of the shares of the stock are sold short. View ADC Therapeutics' Short Interest. When is ADC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ADCT earnings forecast. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) released its earnings results on Tuesday, August, 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.14. The business earned $19.28 million during the quarter, compared to analyst estimates of $34.77 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 325.79% and a negative net margin of 98.33%. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX). When did ADC Therapeutics IPO? (ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO. What is ADC Therapeutics' stock symbol? ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT." Who are ADC Therapeutics' major shareholders? ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Prosight Management LP (7.27%), JPMorgan Chase & Co. (3.59%), Goldman Sachs Group Inc. (1.48%), Vantage Consulting Group Inc (1.15%), AlphaCentric Advisors LLC (1.01%) and BlackRock Inc. (0.61%). How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ADC Therapeutics' stock price today? One share of ADCT stock can currently be purchased for approximately $0.81. How much money does ADC Therapeutics make? ADC Therapeutics (NYSE:ADCT) has a market capitalization of $62.10 million and generates $184.39 million in revenue each year. The company earns $-155,800,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. How many employees does ADC Therapeutics have? The company employs 317 workers across the globe. How can I contact ADC Therapeutics? The official website for the company is www.adctherapeutics.com. The company can be reached via phone at 41-21-653-0200 or via email at amanda.hamilton@adctherapeutics.com. This page (NYSE:ADCT) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.